• Silo Pharma issued 165,000 common shares in an unregistered sale tied to an asset purchase agreement signed Aug. 18, 2026.
• Stock went to Parkview Consulting as consideration for software, technology, domain names, related intellectual property.
• Shares carry a lock-up until the earlier of 12 months, a change in control, or company consent.
• Transaction relied on the Securities Act Section 4(a)(2) private placement exemption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-091783), on August 19, 2026, and is solely responsible for the information contained therein.